Latest & greatest articles for escitalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on escitalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on escitalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for escitalopram

42. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder

Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder Armstrong E P, Skrepnek G H, Erder M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two selective serotonin re-uptake inhibitors (SSRIs), escitalopram and sertraline, for the treatment of major depressive disorder (MDD). Escitalopram was initially given at 10 mg/day; the dose was assumed to increase to 20 mg/day if the patient did not respond to the initial dose. Sertraline was initially given at 50 mg/day

NHS Economic Evaluation Database.2007

43. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Fantino B, Moore N, Verdoux H, Auray J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the relative cost-effectiveness of escitalopram (ESC) compared with citalopram (CIT) for the first-line treatment of patients aged 18 to 65 years with major depressive disorder. The authors concluded that ECS was the preferred strategy as it was more effective and less expensive than CIT from the perspective of the health care payer. The study methodology was of good quality

NHS Economic Evaluation Database.2007

44. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary (...) care Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in the primary

NHS Economic Evaluation Database.2007

45. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom

Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom Jorgensen T R, Stein D J, Despiegel N, Drost P B, Hemels M E, Baldwin D S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared escitalopram (10 to 20 mg/day) and paroxetine (20 to 50 mg/day) as the first-line treatment for generalised anxiety disorder (GAD). Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2006

47. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder Fernandez J L, Montgomery S, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of escitalopram, a selective serotonin reuptake inhibitor, in the treatment of major depressive disorder (MMD). The comparator was venlafaxine RX, a serotonin noradrenaline (norepinephrine) reuptake inhibitor with established efficacy in MMD. Type of intervention Treatment. Economic study type Cost-utility analysis

NHS Economic Evaluation Database.2005

48. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium Demyttenaere K, Hemels M E, Hudry J, Annemans L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies compared were escitalopram (10 - 20 mg/day), citalopram (20 - 40 mg/day) and venlafaxine (75 - 150 mg/day) as first-line treatment for major depressive disorder (MDD). MDD was defined as baseline

NHS Economic Evaluation Database.2005

49. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom Wade A G, Toumi I, Hemels M E H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Escitalopram was compared with citalopram for the treatment of severe depression. The dose of escitalopram was 20 mg/day and that of citalopram 40 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The target population

NHS Economic Evaluation Database.2005

50. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK Wade A G, Toumi (...) I, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three therapies for the treatment of major depressive disorder (MDD) were examined. These were escitalopram (ESC; 10 - 20 mg daily), citalopram (CIT; 20 - 40 mg

NHS Economic Evaluation Database.2005

51. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany Kulp W, Graf von der Schulenburg J M, Greiner W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions examined in the study were escitalopram (ESC) and venlafaxine XR (VEN), two first-line treatments for patients with unipolar depression. ESC was given at 10mg/day and VEN was given at 75mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

NHS Economic Evaluation Database.2005